Australia markets closed
  • ALL ORDS

    6,762.40
    +71.00 (+1.06%)
     
  • ASX 200

    6,578.70
    +50.30 (+0.77%)
     
  • AUD/USD

    0.6944
    +0.0046 (+0.66%)
     
  • OIL

    107.06
    +2.79 (+2.68%)
     
  • GOLD

    1,828.10
    -1.70 (-0.09%)
     
  • BTC-AUD

    30,728.14
    +45.91 (+0.15%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • AUD/EUR

    0.6575
    +0.0025 (+0.38%)
     
  • AUD/NZD

    1.0996
    +0.0016 (+0.14%)
     
  • NZX 50

    10,813.92
    +135.25 (+1.27%)
     
  • NASDAQ

    12,105.85
    +408.17 (+3.49%)
     
  • FTSE

    7,208.81
    +188.36 (+2.68%)
     
  • Dow Jones

    31,500.68
    +823.32 (+2.68%)
     
  • DAX

    13,118.13
    +205.54 (+1.59%)
     
  • Hang Seng

    21,719.06
    +445.19 (+2.09%)
     
  • NIKKEI 225

    26,491.97
    +320.72 (+1.23%)
     

Genetic Signatures (ASX:GSS) shareholders have earned a 26% CAGR over the last five years

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on a lighter note, a good company can see its share price rise well over 100%. Long term Genetic Signatures Limited (ASX:GSS) shareholders would be well aware of this, since the stock is up 217% in five years. It's down 3.6% in the last seven days.

So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.

See our latest analysis for Genetic Signatures

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During the last half decade, Genetic Signatures became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

earnings-per-share-growth
earnings-per-share-growth

It is of course excellent to see how Genetic Signatures has grown profits over the years, but the future is more important for shareholders. This free interactive report on Genetic Signatures' balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

Investors in Genetic Signatures had a tough year, with a total loss of 23%, against a market gain of about 9.6%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 26% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should learn about the 3 warning signs we've spotted with Genetic Signatures (including 1 which is a bit unpleasant) .

Of course Genetic Signatures may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting